Show simple item record

dc.contributor.authorSankhe, R
dc.contributor.authorKinra, M
dc.contributor.authorMudgal, J
dc.contributor.authorArora, D
dc.contributor.authorNampoothiri, M
dc.date.accessioned2019-11-07T03:38:43Z
dc.date.available2019-11-07T03:38:43Z
dc.date.issued2019
dc.identifier.issn1537-6516
dc.identifier.doi10.1080/15376516.2019.1669246
dc.identifier.urihttp://hdl.handle.net/10072/388964
dc.description.abstractNeprilysin (NEP) is an endogenously induced peptidase for modulating production and degradation of various peptides in humans. It is most abundantly present in kidney and regulates the intrinsic renal homeostatic mechanism. Recently, drugs inhibiting NEP have been approved for the use in heart failure. In the context of increased prevalence of ischemia associated renal failure, NEP could be an attractive target for treating kidney failure. In the kidney, targeting NEP may possess potential benefits as well as adverse consequences. The unfavorable outcomes of NEP are mainly attributed to the degradation of the natriuretic peptides (NPs). NPs are involved in the inhibition of the renin–angiotensin–aldosterone system (RAAS) and activation of the sympathetic system contributing to the tubular and glomerular injury. In contrary, NEP exerts the beneficial effect by converting angiotensin-1 (Ang I) to angiotensin-(1–7) (Ang-(1–7)), thus activating MAS-related G-protein coupled receptor. MAS receptor antagonizes angiotensin type I receptor (AT-1R), reduces reactive oxygen species (ROS) and inflammation, thus ameliorating renal injury. However, the association of NEP with complex cascades of renal ischemia remains vague. Therefore, there is a need to evaluate the putative mechanism of NEP and its overlap with other signaling cascades in conditions of renal ischemia.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherInforma UK Limited
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto12
dc.relation.ispartofjournalToxicology Mechanisms and Methods
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode1115
dc.titleNeprilysin, the kidney brush border neutral proteinase: a possible potential target for ischemic renal injury
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSankhe, R; Kinra, M; Mudgal, J; Arora, D; Nampoothiri, M, Neprilysin, the kidney brush border neutral proteinase: a possible potential target for ischemic renal injury, Toxicology Mechanisms and Methods, pp. 1-12
dc.date.updated2019-11-04T05:24:42Z
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version
gro.hasfulltextNo Full Text
gro.griffith.authorArora, Devinder S.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record